Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Bendavia Clear all

Conditions: Primary Mitochondrial Disease
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more

Conditions: Healthy
Interventions: MTP-131 (Bendavia™); Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Age-related Macular Degeneration
Interventions: Subcutaneous elamipretide through the elamipretide delivery system, Subcutaneos placebo through the elamipretide delivery system; Combination Product
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 37
States / cities: Peoria, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more

Conditions: Reperfusion Injury, STEMI
Interventions: Bendavia (MTP-131), Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Port Orange, Florida • Detroit, Michigan • Omaha, Nebraska

Conditions: Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Normal and Impaired Renal Function
Interventions: MTP-131; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Maimi, Florida

Conditions: Healthy Volunteers
Interventions: Bendavia 10mg, Bendavia 50mg, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Unfractionated heparin (UFH), Bendavia, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
Interventions: Bendavia, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Age-Related Macular Degeneration
Interventions: Elamipretide; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Fuchs' Corneal Endothelial Dystrophy (FCED)
Interventions: Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Edgewood, Kentucky • Boston, Massachusetts

Conditions: Healthy
Interventions: Bendavia 10mg, Bendavia 50mg, Bendavia 100mg, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Mitochondrial Myopathy
Interventions: elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose), Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more

Conditions: Healthy Volunteers
Interventions: Bendavia, Sterile saline (0.9%), Cigarette smoking; Drug · Other
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Leber's Hereditary Optic Neuropathy
Interventions: elamipretide (MTP-131) 1% topical ophthalmic solution, Vehicle topical ophthalmic solution; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Pasadena, California

Search by objective public record fields.

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy